Article Details
Retrieved on: 2021-04-26 10:18:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Meanwhile, Alexion's follow-up to Soliris – Ultomiris (ravulizumab) – is also in late-stage clinical development as an infusion for NMOSD, although the ...
Article found on: pharmaphorum.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here